Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 287

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 287
---
 statement/prospectus may prevent a U.S. holder from satisfying the applicable holding period requirements with respect to the dividends received deduction or the preferential tax rate on qualified dividend income, as the case may be.

Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock or Warrants . If our redemption of a U.S. holder’s shares of our common stock is treated as a sale or other taxable disposition, as discussed above under the section entitled “ Redemption of Our Common Stock ,” and in the event of any future sale or other taxable disposition of ParentCo Common Stock or ParentCo warrants, a U.S. holder generally will recognize capital gain or loss in an amount equal to the difference between (i) the sum of the amount of cash and the fair market value of any property received in such disposition and (ii) the U.S. holder’s adjusted tax basis in our common stock, ParentCo Common Stock or ParentCo warrants so disposed of. A U.S. holder’s adjusted tax basis in our common stock, ParentCo Common Stock, or ParentCo warrants generally will equal the U.S. holder’s acquisition cost less any prior distributions paid (or deemed paid) to such U.S. holder treated as a return of capital. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. holder’s holding period for our common stock, ParentCo Common Stock or ParentCo

<div align='center'>143</div>

TABLE OF CONTENTS

warrants so disposed of exceeds one year. It is unclear, however, whether the redemption rights with respect to our common stock described in this proxy statement/prospectus may suspend the running of the applicable holding period for this purpose. Long-term capital gains recognized by non-corporate U.S. holders will be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to limitations.

Exercise or Lapse of a ParentCo Warrant . Except as discussed below with respect to the cashless exercise of a ParentCo warrant, a U.S. holder will not recognize taxable gain or loss on the acquisition of ParentCo Common Stock upon exercise of a ParentCo warrant for cash. The U.S. holder’s tax basis in the share of ParentCo Common Stock received upon exercise of the ParentCo warrant will be an amount equal to the sum of the U.S. holder’s initial investment in the ParentCo warrant and the exercise price. The U.S. holder’s holding period for the ParentCo Common Stock received upon